Abstract Number: 1817 • 2012 ACR/ARHP Annual Meeting
The Role of Repeating Tuberculin Skin Tests During Biologic Therapy
The Role of Repeating Tuberculin Skin Tests during Biologic TherapyBackground/Purpose: Prior to starting biologic therapy, it is recommended that all patients be screened for tuberculosis…Abstract Number: 495 • 2012 ACR/ARHP Annual Meeting
Comparison of Discontinuation Rates by Biologic Since 1998 in US Patients with Rheumatoid Arthritis
Background/Purpose: Since discontinuation may be a surrogate for ineffectiveness, we measured rates and reasons for biologic discontinuation in a real-world setting. Methods: From 1998 to…Abstract Number: 1698 • 2012 ACR/ARHP Annual Meeting
Predictors of Discontinuation of Biologics in 2,281 US Patients with Rheumatoid Arthritis
Background/Purpose: Identifying predictors of discontinuation of biologic treatment for Rheumatoid Arthritis (RA) has clinical and research importance given the chronicity of RA and high costs…Abstract Number: 500 • 2012 ACR/ARHP Annual Meeting
Comparison of Tolerability Between Tumor Necrosis Factor-Inhibitors and Tocilizumab for the Treatment of Rheumatoid Arthritis
Background/Purpose: Some patients with rheumatoid arthritis (RA) receiving tumor necrosis factor-inhibitors (TNF-Is) show inadequate response to TNF-Is. But it has not been clarified what is…Abstract Number: 1684 • 2012 ACR/ARHP Annual Meeting
Increased Risk of Major Cardiovascular Events in a Nationwide Cohort of Rheumatoid Arthritis Patients Treated with Biological Agents
Background/Purpose: Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease, but in contrast to the well-established risk of myocardial infarction (MI), the…Abstract Number: 457 • 2012 ACR/ARHP Annual Meeting
Biologic Disease-Modifying Anti-Rheumatic Drugs and the Risk of Non-Vertebral Osteoporotic Fractures in Patients with Rheumatoid Arthritis Aged 50 Years and Over
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) may interfere with bone remodelling. Inflammation mediators such as TNF-α stimulate osteoclast formation which favors bone destruction. Small…Abstract Number: 1642 • 2012 ACR/ARHP Annual Meeting
Biologics and Mortality Risk in Rheumatoid Arthritis – Results of a Population Based Study
Background/Purpose: Biologic agents, due to their effect on disease activity, may reduce the risk of premature mortality in rheumatoid arthritis (RA). We evaluated the association…Abstract Number: 446 • 2012 ACR/ARHP Annual Meeting
Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Rheumatoid Arthritis Patients
Background/Purpose: Although there is much discussion regarding when to initiate a biological agent in rheumatoid arthritis (RA) patients, data on when to stop these agents…Abstract Number: 1644 • 2012 ACR/ARHP Annual Meeting
Enhanced Pharmacovigilance Reporting of Malignancies in Children and Young Adults Taking Etanercept
Background/Purpose: Recent reports suggest an increased rate of malignancy in children with juvenile idiopathic arthritis (JIA) (Simard, A&R 2010;62:3776; Beukelman A&R 2012;64:1263). In 2011, the…Abstract Number: 388 • 2012 ACR/ARHP Annual Meeting
Retention Rate of the Anti-TNF Biologics in the Treatment of Rheumatic Diseases and Predictive Factors for Drug Withdrawal: Data From the Hong Kong Biologics Registry
Background/Purpose: To study the retention rate of the anti-TNF biologics in the treatment of rheumatic diseases and the associated factors for drug withdrawal Methods: Data…
- « Previous Page
- 1
- …
- 4
- 5
- 6